- ISIN
- US4831191030
- CUSIP
- 483119103
- Sector
- Healthcare
- IPO Date
- Jul 20, 2017
Highlights
- EPS (TTM)
- -$5.29
- Total Revenue (TTM)
- $254.00K
- Gross Profit (TTM)
- -$8.00K
- EBITDA (TTM)
- -$30.98M
- Year Range
- $2.10 - $1,030.00
- Target Price
- $18.25
- ROA (TTM)
- -377.67%
- ROE (TTM)
- -512.31%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KALA Performance Chart
Kala Pharmaceuticals, Inc. (KALA) is down 91.9% since the beginning of the year. At $2 per share, KALA is trading 99.8% below its 52-week high of $1,030. Investors who bought $1,000 worth of KALA shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
Kala Pharmaceuticals, Inc. (KALA) has returned -91.94% so far this year and -98.90% over the past 12 months.
Kala Pharmaceuticals, Inc.
- 1D
- -6.28%
- 1M
- -58.52%
- YTD
- -91.94%
- 6M
- -95.16%
- 1Y
- -98.90%
- 3Y*
- -86.05%
- 5Y*
- -82.75%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
KALA Monthly Returns History
Based on dividend-adjusted daily data since Jul 20, 2017, KALA's average daily return is -0.14%, while the average monthly return is -0.20%.
Historically, 35% of months were positive and 65% were negative. The best month was Dec 2022 with a return of +621.2%, while the worst month was Sep 2025 at -86.4%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, KALA closed higher 43% of trading days. The best single day was Dec 28, 2022 with a return of +218.4%, while the worst single day was Sep 29, 2025 at -89.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.66% | -28.30% | -54.45% | -39.28% | -57.56% | 0.45% | -91.94% | ||||||
| 2025 | 32.56% | -24.67% | -17.32% | -30.72% | -6.30% | 27.96% | 42.23% | 65.73% | -86.36% | -49.02% | 23.86% | -42.46% | -91.99% |
| 2024 | -0.71% | 3.31% | 11.00% | -14.43% | -1.47% | 5.51% | -8.32% | -10.00% | -2.57% | 23.51% | -2.59% | 1.20% | -0.86% |
| 2023 | -54.55% | -41.58% | 48.57% | 4.78% | -9.32% | 2.03% | 3.02% | -10.71% | -33.68% | -22.47% | -12.32% | 15.70% | -81.65% |
| 2022 | -26.88% | -25.17% | 108.46% | -52.93% | -46.39% | -13.84% | 10.00% | -7.88% | -27.17% | -42.64% | -16.69% | 621.17% | -36.94% |
| 2021 | 9.59% | -0.27% | -9.04% | 14.69% | -26.91% | -6.19% | -34.91% | -2.03% | -22.49% | -33.59% | 9.20% | -36.32% | -82.15% |
Benchmark Metrics
Kala Pharmaceuticals, Inc. has an annualized alpha of -36.51%, beta of 0.75, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 21, 2017.
- This stock participated in 195.05% of S&P 500 Index downside but only -111.57% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -36.51%
- Beta
- 0.75
- R²
- 0.01
- Upside Capture
- -111.57%
- Downside Capture
- 195.05%
Return for Risk
Risk / Return Rank
KALA ranks 8 for risk / return — in the bottom 8% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kala Pharmaceuticals, Inc. (KALA) and compare them to S&P 500 Index.
| KALA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.85 | ||
| Sortino ratioReturn per unit of downside risk | -4.83 | ||
| Omega ratioGain probability vs. loss probability | 0.75 | 1.41 | -0.65 |
| Calmar ratioReturn relative to maximum drawdown | -0.99 | 2.93 | -3.92 |
| Martin ratioReturn relative to average drawdown | -1.23 | 13.52 | -14.75 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kala Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kala Pharmaceuticals, Inc. was 100.00%, occurring on May 26, 2026. The portfolio has not yet recovered.
The current Kala Pharmaceuticals, Inc. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%May 2026 | 8y 8mo | — | 8y 8moSep 2017 - now |
2017 pullback2017 | -6.48%Aug 2017 | 10d | 4d | 14dJul 2017 - Aug 2017 |
2017 pullback2017 | -4.43%Aug 2017 | 1d | 10d | 11dAug 2017 - Aug 2017 |
2017 pullback2017 | -2.27%Jul 2017 | 1d | 1d | 2dJul 2017 - Jul 2017 |
2017 pullback2017 | -1.51%Sep 2017 | 1d | 4d | 5dSep 2017 - Sep 2017 |
Drawdown Indicators
| KALA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -99.78% | -9.10% | -90.68% |
Max Drawdown (3Y)Largest decline over 3 years | -99.78% | -18.90% | -80.88% |
Max Drawdown (5Y)Largest decline over 5 years | -99.99% | -25.43% | -74.56% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -0.74% | -99.26% |
Average DrawdownAverage peak-to-trough decline | -82.03% | -10.72% | -71.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 80.31% | 1.97% | +78.34% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kala Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kala Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KALA relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, KALA has a P/S ratio of 59.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KALA
Add Kala Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KALA